PTPN11 and neoplasm: Within the PD-1 signaling pathway, SHP2 suppresses T-cell activation by dephosphorylating critical components of the T-cell receptor (TCR) complex, including CD28 and ZAP70, thereby impairing the host’s anti-tumor immune response [20,21,22].